Pharmaceutical Chemistry Journal

, Volume 30, Issue 12, pp 760–763 | Cite as

Computer-aided prediction of prodrug activity using the pass system

  • Yu. V. Borodina
  • D. A. Filimonov
  • V. V. Poroikov
Search for New Drugs

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. A. Filimonov, V. V. Poroikov, E. I. Karaicheva, et al.,Éksp. Klin. Farmakol.,58(2), 56–62 (1995).Google Scholar
  2. 2.
    D. A. Filimonov and V. V. Poroikov,Bioactive Compound Design: Possibilities for Industrial Use, BIOS Scientific Publishers (1996), pp. 47–56.Google Scholar
  3. 3.
    V. V. Poroikov and D. A. Filimonov,QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications, Prous Science Publishers, Barcelona (1996) p. 49–50.Google Scholar
  4. 4.
    Prodrugs: Chemical Aspect, in:Itogi Nauki Tekhn., Ser. Org. Khim., Vol 19, VINITI, Moscow (1991).Google Scholar
  5. 5.
    V. M. Vrudhula, H. P. Svensson, and P. D. Senter,J. Med. Chem.,38(8), 1380–1385 (1995).Google Scholar
  6. 6.
    D. Bonnaffe, B. Dupraz, J. Ughetto-Monfrin, et al.,Nucleosides Nucleotides,14(3–5), 783–787 (1995).Google Scholar
  7. 7.
    L. El Kihel, P. M. Loiseau, J. Bourass, et al.,Arzneim.-Forsch.,44(11), 1259–1264 (1994).Google Scholar
  8. 8.
    J. C. Roberts, K. E. Koch, S. R. Detrick, et al..Radiat. Res.,143(2), 203–213 (1995).Google Scholar
  9. 9.
    G. R. Pettit, C. Temple, V. L. Narayanan, et al.,Anti-Cancer Drug Design,10(4), 299–309 (1995).Google Scholar
  10. 10.
    J. P. Burkhart, J. R. Koehl, S. Mehdi, et al.,J. Med. Chem.,38(2), 223–233 (1995).Google Scholar
  11. 11.
    G. K. E. Scriba, D. M. Lambert, and J. H. Poupaert,J. Pharm. Sci.,84(3), 300–302 (1995).Google Scholar
  12. 12.
    T. Kawaguchi, H. Sakairi, S. Kimura, et al.,Chem. Pharm. Bull.,43(3), 501–504 (1995).Google Scholar
  13. 13.
    F. M. Menger, Y. Guo, and A. S. Lee,Bioconjugate Chem.,5(2), 162–166 (1994).Google Scholar
  14. 14.
    K.-Y. Moon, F. N. Shirota, N. Baturay, et al.,J. Med. Chem.,38(5), 848–851 (1995).Google Scholar
  15. 15.
    X. Guo, M. Lernertung, H. X. Chen, et al.,Biochem. Pharmacol.,49(8), 1111–1116 (1995).Google Scholar
  16. 16.
    A.-S. Charvet, M. Camplo, and P. Faury,J. Med. Chem.,37(14), 2216–2223 (1994).Google Scholar
  17. 17.
    K. Shanmuganathan, T. Koudiakova, S. Nampalli, et al.,J. Med. Chem.,37(6), 821–827 (1994).Google Scholar
  18. 18.
    T. C. Burnette, J. A. Harrington, J. E. Reardon, et al.,J. Biol. Chem.,270(26), 15827–15831 (1995).Google Scholar
  19. 19.
    J. H. Bateson, G. Burton, S. C. M. Fell, et al.,J. Antibiot.,47(2), 253–256 (1994).Google Scholar
  20. 20.
    S. K. Davidsen, J. B. Summers, D. H. Albert, et al.,J. Med. Chem.,37(26), 4423–4429 (1994).Google Scholar
  21. 21.
    T. J. Carty, A. Marfat, and P. F. Moore,Agents Actions,39(3–4), 157–165 (1993).Google Scholar
  22. 22.
    J. Takata, Y. Karube, Y. Nagata, et al.,J. Pharm. Sci.,84(1), 96–100 (1995).Google Scholar
  23. 23.
    J. Patel, M. J. Katovich, K. B. Sloan, et al.,J. Pharm. Sci.,84(2), 174–178 (1995).Google Scholar
  24. 24.
    R. Kumar, L. Wang, L. I. Wiebe, et al.,J. Med. Chem.,37(25), 4297–4306 (1994).Google Scholar
  25. 25.
    H. Ford, Jr., M. A. Siddiqui, et al.,J. Med. Chem.,38(7), 1189–1195 (1995).Google Scholar
  26. 26.
    C. Desseaux, C. Gouyette, Y. Henin, et al.,Tetrahedron,51(24), 6739–6756 (1995).Google Scholar
  27. 27.
    R. B. Greenwald, A. Pendri, and D. Bolikal,J. Org. Chem.,60(2), 331–336 (1995).Google Scholar
  28. 28.
    R. G. G. Leenders, K. A. A. Gerrits, R. Ruijtenbeek, et al.,Tetrahedron Lett.,36(10), 1701–1704 (1995).Google Scholar
  29. 29.
    D. E. Kerr,Cancer Res.,55(16), 3558–3563 (1995).Google Scholar
  30. 30.
    V. M. Vrudhula, H. P. Svensson, K. A. Kennedy, et al.,Bioconjugate Chem.,4(5), 334–340 (1993).Google Scholar
  31. 31.
    H. Okada, T. Koyanagi, and N. Yamada,Chem. Pharm. Bull.,42(1), 57–61 (1994).Google Scholar
  32. 32.
    C. J. Springer, I. Niculescu-Duvaz, and R. B. Pedley,J. Med. Chem.,37(15), 2361–2370 (1994).Google Scholar
  33. 33.
    K. A. Lamb, S. P. Denyer, F. D. Sanderson, et al.,J. Pharm. Pharmacol.,46, 965–973 (1994).Google Scholar
  34. 34.
    C. Clerici, G. Gentili, E. Boschetti, et al.,Digestive Diseases Sci.,39(12), 2601–2606 (1994).Google Scholar
  35. 35.
    S. De Lombaert, M. D. Erion, J. Tan, et al.,J. Med. Chem.,37(4), 498–511 (1994).Google Scholar
  36. 36.
    K. Watanabe, H. Hayashi, and Y. Mori,Pharmacol. Res.,28(1), 59–70 (1993).Google Scholar
  37. 37.
    S. De Lombaert, L. Blanchard, C. Berry, et al.,Bioorg. Med. Chem. Lett.,5(2), 151–154 (1995).Google Scholar
  38. 38.
    G. K. E. Scriba, D. M. Lambert, and J. H. Poupaert,J. Pharm. Pharmacol.,47, 197–203 (1995).Google Scholar
  39. 39.
    G. K. E. Scriba,Arch. Pharm.,326(8), 477–481 (1993).Google Scholar
  40. 40.
    H. T. Nagasawa, S. P. Kawle, J. A. Elberling, et al.,J. Med. Chem.,38(11), 1865–1871 (1995).Google Scholar
  41. 41.
    A. Nudelman and R. Keiner,Arch. Pharm. 326(11), 907–909 (1993).Google Scholar
  42. 42.
    S. Ahmed, T. Imai, and M. Otagiri,J. Pharm. Sci.,84(7), 877–883 (1995).Google Scholar
  43. 43.
    C. Meier, L. Habel, W. Laux, et al.,Nucleosides Nucleotides,14(3–5), 759–762 (1995).Google Scholar
  44. 44.
    G. R. Pettit, S. Freeman, M. J. Simpson, et al.,Anti-Cancer Drug Design,10(3), 243–250 (1995).Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Yu. V. Borodina
    • 1
  • D. A. Filimonov
    • 1
  • V. V. Poroikov
    • 1
  1. 1.Institute of Biomedical ChemistryRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations